Creator Roux Sparks Conversation After Sharing Weight Loss Journey

The video, titled "before reta vs…," highlights the physical changes Roux has undergone while utilizing the investigational weight-loss drug. While some long-term followers have voiced a preference for her past appearance, the creator has met the feedback with characteristic openness. She maintains that her decision to share the journey is personal rather than an endorsement, framing the shift as just another chapter in the life content she regularly produces for her audience.

Roux’s disclosure brings a personal face to the broader, often intense, online discourse surrounding GLP-1 and triple-agonist medications. Retatrutide, the drug colloquially dubbed "Reta" by social media users, is currently under development by Eli Lilly. Although the compound has generated significant buzz due to its performance in clinical trials targeting GIP, GLP-1, and glucagon receptors, it has yet to receive FDA approval for general use. Despite its status as an investigational treatment, interest in the drug continues to surge across social platforms, mirroring the ongoing cultural fascination with medical weight-loss interventions.